Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609230 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02609230 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 33 participants.
The verdict
NCT02609230, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
Interventions
- DRUG ONC-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609230
The ClinicalTrials.gov registry entry for NCT02609230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONC-201 is the first listed.
NCT02609230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02609230 about?
NCT02609230 is a clinical study titled "A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma". This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
What is the current status of trial NCT02609230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-11-05. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT02609230?
The interventions under investigation include: ONC-201 (DRUG).
Who is sponsoring clinical trial NCT02609230?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.